CBIO
Crescent Biopharma
CBIO
CBIO
48 hedge funds and large institutions have $83.1M invested in Crescent Biopharma in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.03% more ownership
Funds ownership: 0.49% → 0.52% (+0.03%)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Holders
48
Holding in Top 10
–
Calls
$1.04M
Puts
$5K
Top Buyers
| 1 | +$1.69M | |
| 2 | +$1.2M | |
| 3 | +$952K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$633K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$405K |
Top Sellers
| 1 | -$816K | |
| 2 | -$368K | |
| 3 | -$227K | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$142K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$118K |